# Richard S. Finn

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/richard-s-finn/

## Facts

| Field | Value |
| --- | --- |
| Citations | 83,418 |
| Field | Hepatocellular Carcinoma Treatment and Prognosis |
| h-index | 101 |
| i10-index | 283 |
| Last Known Institution | University of California, Los Angeles |
| OpenAlex ID | https://openalex.org/A5073989429 |
| ORCID iD | https://orcid.org/0000-0003-2494-2126 |
| Works | 759 |

## Researcher papers

- [AASLD guidelines for the treatment of hepatocellular carcinoma](https://scholariq.org/papers/aasld-guidelines-for-the-treatment-of-hepatocellular-carcinoma/)
- [Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial](https://scholariq.org/papers/pembrolizumab-in-patients-with-advanced-hepatocellular-carcinoma-previously/)
- [Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-after-sorafenib-in-patients-with-advanced-hepatocellular-carcinoma/)
- [Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-in-combination-with-gemcitabine-and-cisplatin-compared-with/)
- [Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-lenvatinib-plus-placebo-for-advanced/)
- [Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial](https://scholariq.org/papers/brivanib-as-adjuvant-therapy-to-transarterial-chemoembolization-in-patients-with/)
- [A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer](https://scholariq.org/papers/a-phase-ii-and-biomarker-study-of-ramucirumab-a-human-monoclonal-antibody/)

## Researcher topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)

## Researcher university

- [University of California, Los Angeles](https://scholariq.org/institutions/university-of-california-los-angeles/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.